HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


US Cosmetics Companies Doing Gap Analysis, Awaiting FDA Instruction In MoCRA’s First Year

Executive Summary

Amin Talati Wasserman attorney Angela Diesch discusses the priorities, questions and concerns among companies facing end-of-year deadlines under the Modernization of Cosmetic Regulations Act enacted in the final days of 2022.

You may also be interested in...

Cosmetic Manufacturers Preparing For MoCRA Safety Substantiation Should Look To EU – Attorneys

Manufacturers looking for a model of safety substantiation in order to comply with the US Modernization of Cosmetics Regulation Act of 2022 should consider the framework required by the EU’s Cosmetic Products Regulation, says Steptoe & Johnson associate Surya Kundu. Attorneys also discussed new requirements for adverse event reporting during a FDLI webinar on MoCRA.

FDA’s Linda Katz Addresses Why VCRP Wouldn’t Work For Cosmetics Registration Under MoCRA

The cosmetics office director assured attendees of a 27 April FDLI webinar that the agency’s launch of a new platform for cosmetics registration and product listing will afford companies sufficient time to comply with new requirements under the Modernization of Cosmetic Regulations Act.

MoCRA Check-In: FDA Guidance Urgently Needed As Year-End Compliance Deadlines Loom

John Bailey, independent advisor for colors and cosmetics at EAS Consulting Group, is checking in with HBW Insight periodically in 2023 to offer his views on developments under the US Modernization of Cosmetic Regulations Act of 2022. Here he discusses the urgent need for FDA guidance as deadlines creep closer for registration, product listing, safety substantiation, and adverse event reporting.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts